DRug-Induced Liver Injury: Mechanisms, types and biomarkers

Current Medicinal Chemistry

Volumn 20, Issue 24, 2013, Pages 3011-3021

  Vinken, M ^a   Maes, M ^a   Vanhaecke, T ^a   Rogiers, V ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Biomarkers; Cholestasis; Drugs; Fibrosis; Hepatitis; Hepatotoxicity; Mechanisms; Steatosis

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BIOLOGICAL MARKER; CHLORPROMAZINE; CLARITHROMYCIN; CYCLOSPORIN A; DANTROLENE; DISULFIRAM; ERYTHROMYCIN ESTOLATE; ESTROGEN; FLUCLOXACILLIN; FLUTAMIDE; GENTAMICIN; GLIBENCLAMIDE; IMIPRAMINE; ISONIAZID; LISINOPRIL; METHOTREXATE; MINOCYCLINE; NIMESULIDE; NITROFURANTOIN; PARACETAMOL; PHENYTOIN; PIROXICAM; RIFAMPICIN; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE HEPATITIS; APOPTOSIS; ARTICLE; CELL DEATH; CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CLINICAL CHEMISTRY; CLINICAL FEATURE; DISEASE MODEL; DRUG MEGADOSE; DRUG METABOLISM; EPIGENETICS; FATTY ACID SYNTHESIS; FATTY LIVER; FOLIC ACID DEFICIENCY; HEPATITIS; HISTOPATHOLOGY; HUMAN; INTRAHEPATIC CHOLESTASIS; LIPIDOSIS; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER MITOCHONDRION; LIVER NECROSIS; LOW DRUG DOSE; METABOLOMICS; MITOCHONDRIAL PERMEABILITY; MOLECULAR PATHOLOGY; NONHUMAN; PROTEOMICS; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; TRANSCRIPTOMICS;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CHOLESTASIS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATTY LIVER; HUMANS; LIVER; LIVER CIRRHOSIS; METABOLOMICS; MITOCHONDRIA, LIVER; PROTEOMICS; RISK FACTORS;

EID: 84880302130     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320240006     Document Type: Article

References (169)

1. Przybylak, K.R.; Cronin, M.T., In silico models for drug-induced liver injury: current status. Expert Opin. Drug Metab. Toxicol., 2012, 8, 201-217.
2. Faa, G.; Ekstrom, J.; Castagnola, M.; Gibo, Y.; Ottonello, G.; Fanos, V., A developmental approach to drug-induced liver injury in newborns and children. Curr. Med. Chem., 2012, 19, 4581-4594.
3. Holt, M.P.; Ju, C., Mechanisms of drug-induced liver injury. AAPS J., 2006, 8, E48-54.
4. Verma, S.; Kaplowitz, N., Diagnosis, management and prevention of drug-induced liver injury. Gut, 2009, 58, 1555-1564.
5. Andrade, R.J.; Agundez, J.A.; Lucena, M.I.; Martinez, C.; Cueto, R.; Garcia-Martin, E., Pharmacogenomics in drug induced liver injury. Curr. Drug Metab., 2009, 10, 956-970.
6. Andrade, R.J.; Robles, M.; Ulzurrun, E.; Lucena, M.I., Druginduced liver injury: insights from genetic studies. Pharmacogenomics, 2009, 10, 1467-1487.
7. Blomme, E.A.; Yang, Y.; Waring, J.F., Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett., 2009, 186, 22-31.
8. Scott, D.A.; Gholson, C.F.; Netchvolodoff, C.V.; Ray, M.; Gonzalez, E.; Bacon, B.R., Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy. Am. J. Gastroenterol., 1991, 86, 500-502.
9. Aires, C.C.; Ijlst, L.; Stet, F.; Prip-Buus, C.; de Almeida, I.T.; Duran, M.; Wanders, R.J.; Silva, M.F., Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem. Pharmacol., 2010, 79, 792-799.
10. Adams, D.H.; Ju, C.; Ramaiah, S.K.; Uetrecht, J.; Jaeschke, H., Mechanisms of immune-mediated liver injury. Toxicol. Sci., 2010, 115, 307-321.
11. Uetrecht, J., Immunoallergic drug-induced liver injury in humans. Semin. Liver Dis., 2009, 29, 383-392.
12. Guengerich, F.P., Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet., 2011, 26, 3-14.
13. Ramachandran, R.; Kakar, S., Histological patterns in drug-induced liver disease. J. Clin. Pathol., 2009, 62, 481-492.
14. Zimmerman, H.J., Drug-induced liver disease. Clin. Liver Dis., 2000, 4, 73-96.
15. Tujios, S.; Fontana, R.J., Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol., 2011, 8, 202-211.
16. Chalasani, N.; Bjornsson, E., Risk factors for idiosyncratic druginduced liver injury. Gastroenterology, 2010, 138, 2246-2259.
17. Cui, Y.; Paules, R.S., Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics, 2010, 11, 573-585.
18. Bjornsson, E., Drug-induced liver injury in clinical practice. Aliment. Pharmacol. Ther., 2010, 32, 3-13.
19. Russmann, S.; Kullak-Ublick, G.A.; Grattagliano, I., Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem., 2009, 16, 3041-3053.
20. Kis, E.; Ioja, E.; Rajnai, Z.; Jani, M.; Mehn, D.; Heredi-Szabo, K.; Krajcsi, P., BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. Toxicol. In Vitro, 2012, 26, 1294-1299.
21. Han, D.; Shinohara, M.; Ybanez, M.D.; Saberi, B.; Kaplowitz, N., Signal transduction pathways involved in drug-induced liver injury. Handb. Exp. Pharmacol., 2010, 196, 267-310.
22. Hinson, J.A.; Roberts, D.W.; James, L.P., Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol., 2010, 196, 369-405.
23. Jaeschke, H.; Williams, C.D.; Ramachandran, A.; Bajt, M.L., Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int., 2012, 32, 8-20.
24. Srivastava, A.; Maggs, J.L.; Antoine, D.J.; Williams, D.P.; Smith, D.A.; Park, B.K., Role of reactive metabolites in drug-induced hepatotoxicity. Handb. Exp. Pharmacol., 2010, 196, 165-194.
25. Bartolone, J.B.; Birge, R.B.; Sparks, K.; Cohen, S.D.; Khairallah, E.A., Immunochemical analysis of acetaminophen covalent binding to proteins: partial characterization of the major acetaminophenbinding liver proteins. Biochem. Pharmacol., 1988, 37, 4763-4774.
26. Streeter, A.J.; Dahlin, D.C.; Nelson, S.D.; Baillie, T.A., The covalent binding of acetaminophen to protein: evidence for cysteine residues as major sites of arylation in vitro. Chem. Biol. Interact., 1984, 48, 349-366.
27. Jones, D.P.; Lemasters, J.J.; Han, D.; Boelsterli, U.A.; Kaplowitz, N., Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol. Interv., 2010, 10, 98-111.
28. Pessayre, D.; Mansouri, A.; Berson, A.; Fromenty, B., Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol., 2010, 196, 311-365.
29. Fromenty, B.; Pessayre, D., Inhibition of mitochondrial betaoxidation as a mechanism of hepatotoxicity. Pharmacol. Ther., 1995, 67, 101-154.
30. Holt, M.; Ju, C., Drug-induced liver injury. Handb. Exp. Pharmacol., 2010, 196, 3-27.
31. Uetrecht, J., Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 513-539.
32. Bird, G.L.; Williams, R., Detection of antibodies to a halothane metabolite hapten in sera from patients with halothane-Associated hepatitis. J. Hepatol., 1989, 9, 366-373.
33. Bourdi, M.; Larrey, D.; Nataf, J.; Bernuau, J.; Pessayre, D.; Iwasaki, M.; Guengerich, F.P.; Beaune, P.H., Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest., 1990, 85, 1967-1973.
34. Aithal, G.P.; Ramsay, L.; Daly, A.K.; Sonchit, N.; Leathart, J.B.; Alexander, G.; Kenna, J.G.; Caldwell, J.; Day, C.P., Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology, 2004, 39, 1430-1440.
35. Grattagliano, I.; Bonfrate, L.; Diogo, C.V.; Wang, H.H.; Wang, D.Q.; Portincasa, P., Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J. Gastroenterol., 2009, 15, 4865-4876.
36. Roth, R.A.; Ganey, P.E., Animal models of idiosyncratic druginduced liver injury: current status. Crit. Rev. Toxicol., 2011, 41, 723-739.
37. Kharasch, E.D.; Hankins, D.; Mautz, D.; Thummel, K.E., Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet, 1996, 347, 1367-1371.
38. Naisbitt, D.J.; Farrell, J.; Wong, G.; Depta, J.P.; Dodd, C.C.; Hopkins, J.E.; Gibney, C.A.; Chadwick, D.W.; Pichler, W.J.; Pirmohamed, M.; Park, B.K., Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol., 2003, 111, 1393-1403.
39. Blijham, G.H.; Blaauw, I.; Schutte, B.; Mendes de Leon, D.E., Increased numbers of suppressor-cytotoxic cells in a patient with carbamazepine hypersensitivity. J. Immunopharmacol., 1984, 6, 79-85.
40. von Greyerz, S.; Zanni, M.P.; Frutig, K.; Schnyder, B.; Burkhart, C.; Pichler, W.J., Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. J. Immunol., 1999, 162, 595-602.
41. Fisher, J.E.; McKenzie, T.J.; Lillegard, J.B.; Yu, Y.; Juskewitch, J.E.; Nedredal, G.I.; Brunn, G.J.; Yi, E.S.; Malhi, H.; Smyrk, T.C.; Nyberg, S.L., Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure. J. Surg. Res., 2013, 180, 147-155.
42. Lawson, J.A.; Farhood, A.; Hopper, R.D.; Bajt, M.L.; Jaeschke, H., The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol. Sci., 2000, 54, 509-516.
43. Liu, Z.X.; Govindarajan, S.; Kaplowitz, N., Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology, 2004, 127, 1760-1774.
44. Blazka, M.E.; Elwell, M.R.; Holladay, S.D.; Wilson, R.E.; Luster, M.I., Histopathology of acetaminophen-induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol. Pathol., 1996, 24, 181-189.
45. You, Q.; Cheng, L.; Reilly, T.P.; Wegmann, D.; Ju, C., Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology, 2006, 44, 1421-1431.
46. Cheng, L.; You, Q.; Yin, H.; Holt, M.P.; Ju, C., Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem. Pharmacol., 2010, 80, 255-261.
47. Toyoda, Y.; Miyashita, T.; Endo, S.; Tsuneyama, K.; Fukami, T.; Nakajima, M.; Yokoi, T., Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett., 2011, 204, 17-24.
48. Juhaszova, M.; Wang, S.; Zorov, D.B.; Nuss, H.B.; Gleichmann, M.; Mattson, M.P.; Sollott, S.J., The identity and regulation of the mitochondrial permeability transition pore: where the known meets the unknown. Ann. N.Y. Acad. Sci., 2008, 1123, 197-212.
49. Tsujimoto, Y.; Shimizu, S., Role of the mitochondrial membrane permeability transition in cell death. Apoptosis, 2007, 12, 835-840.
50. Pessayre, D.; Fromenty, B.; Berson, A.; Robin, M.A.; Letteron, P.; Moreau, R.; Mansouri, A., Central role of mitochondria in druginduced liver injury. Drug Metab. Rev., 2012, 44, 34-87.
51. Alkhouri, N.; Carter-Kent, C.; Feldstein, A.E., Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert. Rev. Gastroenterol. Hepatol., 2011, 5, 201-212.
52. Au, J.S.; Navarro, V.J.; Rossi, S., Drug-induced liver injury: its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther., 2011, 34, 11-20.
53. Guicciardi, M.E.; Gores, G.J., Apoptosis: a mechanism of acute and chronic liver injury. Gut, 2005, 54, 1024-1033.
54. Malhi, H.; Gores, G.J.; Lemasters, J.J., Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology, 2006, 43, S31-S44.
55. Schulze-Bergkamen, H.; Schuchmann, M.; Fleischer, B.; Galle, P.R., The role of apoptosis versus oncotic necrosis in liver injury: facts or faith? J. Hepatol., 2006, 44, 984-993.
56. St-Pierre, M.V.; Dufour, J.F., Biomarkers for hepatocellular apoptosis in the management of liver diseases. Curr. Pharm. Biotechnol., 2012, 13, 2221-2227.
57. Czaja, A.J., Drug-induced autoimmune-like hepatitis. Dig. Dis. Sci., 2011, 56, 958-976.
58. Lee, V.M.; Cameron, R.G.; Archer, M.C., Zonal location of compensatory hepatocyte proliferation following chemically induced hepatotoxicity in rats and humans. Toxicol. Pathol., 1998, 26, 621-627.
59. Benjamin, S.B.; Goodman, Z.D.; Ishak, K.G.; Zimmerman, H.J.; Irey, N.S., The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology, 1985, 5, 1163-1171.
60. Puppala, A.R.; Steinheber, F.U., Fulminant hepatic failure associated with methyldopa. Am. J. Gastroenterol., 1977, 68, 578-581.
61. Brahm, J.; Brahm, M.; Segovia, R.; Latorre, R.; Zapata, R.; Poniachik, J.; Buckel, E.; Contreras, L., Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann. Hepatol., 2011, 10, 93-98.
62. Sharp, J.R.; Ishak, K.G.; Zimmerman, H.J., Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann. Intern. Med., 1980, 92, 14-19.
63. Malcolm, A.; Heap, T.R.; Eckstein, R.P.; Lunzer, M.R., Minocycline-induced liver injury. Am. J. Gastroenterol., 1996, 91, 1641-1643.
64. Schaller, J.G., Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin "hepatitis" and its clinical significance. Pediatrics, 1978, 62, 916-925.
65. Droste, H.T.; de Vries, R.A., Chronic hepatitis caused by lisinopril. Neth. J. Med., 1995, 46, 95-98.
66. Utili, R.; Boitnott, J.K.; Zimmerman, H.J., Dantrolene-Associated hepatic injury: incidence and character. Gastroenterology, 1977, 72, 610-616.
67. Selroos, O.; Edgren, J., Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin: report of three cases. Acta Med. Scand., 1975, 197, 125-129.
68. Elkayam, O.; Levartovsky, D.; Brautbar, C.; Yaron, M.; Burke, M.; Vardinon, N.; Caspi, D., Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am. J. Med., 1998, 105, 484-487.
69. Arrese, M.; Trauner, M., Molecular aspects of bile formation and cholestasis. Trends Mol. Med., 2003, 9, 558-564.
70. Hirschfield, G.M.; Heathcote, E.J.; Gershwin, M.E., Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology, 2010, 139, 1481-1496.
71. Zollner, G.; Wagner, M.; Trauner, M., Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther., 2010, 126, 228-243.
72. Padda, M.S.; Sanchez, M.; Akhtar, A.J.; Boyer, J.L., Drug-induced cholestasis. Hepatology, 2011, 53, 1377-1387.
73. Maillette de Buy Wenniger, L.; Beuers, U., Bile salts and cholestasis. Dig. Liver Dis., 2010, 42, 409-418.
74. Amacher, D.E., A toxicologist's guide to biomarkers of hepatic response. Hum. Exp. Toxicol., 2002, 21, 253-262.
75. Dawson, S.; Stahl, S.; Paul, N.; Barber, J.; Kenna, J.G., In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug. Metab. Dispos., 2012, 40, 130-138.
76. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G.A.; Meier, P.J., Drug-And estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000, 118, 422-430.
77. Fricker, G.; Fahr, A., Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action? Yale J. Biol. Med., 1997, 70, 379-390.
78. Phillips, M.J.; Oda, M.; Funatsu, K., Evidence for microfilament involvement in norethandrolone-induced intrahepatic cholestasis. Am. J. Pathol., 1978, 93, 729-744.
79. Roman, I.D.; Fernandez-Moreno, M.D.; Fueyo, J.A.; Roma, M.G.; Coleman, R., Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol. Sci., 2003, 71, 276-281.
80. Robenek, H.; Gebhardt, R., Primary cultures of rat hepatocytes as a model system of canalicular development, biliary secretion, and intrahepatic cholestasis. IV: disintegration of bile canaliculi and disturbance of tight junction formation caused by vinblastine. Eur. J. Cell Biol., 1983, 31, 283-289.
81. Cohen, J.C.; Horton, J.D.; Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science, 2011, 332, 1519-1523.
82. Begriche, K.; Massart, J.; Robin, M.A.; Borgne-Sanchez, A.; Fromenty, B., Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol., 2011, 54, 773-794.
83. Amacher, D.E.; Martin, B.A., Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam. Appl. Toxicol., 1997, 40, 256-263.
84. Lelliott, C.J.; Lopez, M.; Curtis, R.K.; Parker, N.; Laudes, M.; Yeo, G.; Jimenez-Linan, M.; Grosse, J.; Saha, A.K.; Wiggins, D.; Hauton, D.; Brand, M.D.; O'Rahilly, S.; Griffin, J.L.; Gibbons, G.F.; Vidal-Puig, A., Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J., 2005, 19, 1108-1119.
85. Chariot, P.; Drogou, I.; de Lacroix-Szmania, I.; Eliezer-Vanerot, M.C.; Chazaud, B.; Lombes, A.; Schaeffer, A.; Zafrani, E.S., Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol., 1999, 30, 156-160.
86. Letteron, P.; Sutton, A.; Mansouri, A.; Fromenty, B.; Pessayre, D., Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38, 133-140.
87. Baronas, E.T.; Lee, J.W.; Alden, C.; Hsieh, F.Y., Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmcol., 2007, 218, 72-78.
88. Gomez-Lechon, M.J.; Tolosa, L.; Castell, J.V.; Donato, M.T., Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project. Toxicol. In Vitro, 2010, 24, 1879-1889.
89. Shi, Q.; Hong, H.; Senior, J.; Tong, W., Biomarkers for druginduced liver injury. Expert Rev. Gastroenterol. Hepatol., 2010, 4, 225-234.
90. Laurent, G.; Carlier, M.B.; Rollman, B.; Van Hoof, F.; Tulkens, P., Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem. Pharmacol., 1982, 31, 3861-3870.
91. Friedman, S.L., Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008, 134, 1655-1669.
92. Baranova, A.; Lal, P.; Birerdinc, A.; Younossi, Z.M., Non-invasive markers for hepatic fibrosis. BMC Gastroenterol., 2011, 11, 91.
93. Friedman, S.L., Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol., 2010, 7, 425-436.
94. Jiao, J.; Friedman, S.L.; Aloman, C., Hepatic fibrosis. Curr. Opin. Gastroenterol., 2009, 25, 223-229.
95. Sanchez-Valle, V.; Chavez-Tapia, N.C.; Uribe, M.; Mendez-Sanchez, N., Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr. Med. Chem., 2012, 19, 4850-4860.
96. Hytiroglou, P.; Tobias, H.; Saxena, R.; Abramidou, M.; Papadimitriou, C.S.; Theise, N.D., The canals of hering might represent a target of methotrexate hepatic toxicity. Am. J. Clin. Pathol., 2004, 121, 324-329.
97. Pagadigorria, C.L.; Marcon, F.; Kelmer-Bracht, A.M.; Bracht, A.; Ishii-Iwamoto, E.L., Effects of methotrexate on calcium flux in rat liver mitochondria, microsomes and plasma membrane vesicles. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 2006, 143, 340-348.
98. Kamen, B.A.; Nylen, P.A.; Camitta, B.M.; Bertino, J.R., Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br. J. Haematol., 1981, 49, 355-360.
99. Kremer, J.M.; Galivan, J.; Streckfuss, A.; Kamen, B., Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum., 1986, 29, 832-835.
100. Chan, E.S.; Montesinos, M.C.; Fernandez, P.; Desai, A.; Delano, D.L.; Yee, H.; Reiss, A.B.; Pillinger, M.H.; Chen, J.F.; Schwarzschild, M.A.; Friedman, S.L.; Cronstein, B.N., Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol., 2006, 148, 1144-1155.
101. Merkel, C.; Montagnese, S., Hepatic venous pressure gradient measurement in clinical hepatology. Dig Liver Dis, 2011, 43, 762-767.
102. Abbattista, T.; Ridolfi, F.; Ciabattoni, E.; Marini, F.; Bendia, E.; Brunelli, E.; Busilacchi, P., Diagnosis of liver cirrhosis by transittime analysis at contrast-enhanced ultrasonography. Radiol. Med., 2008, 113, 860-874.
103. Goyal, N.; Jain, N.; Rachapalli, V.; Cochlin, D.L.; Robinson, M., Non-invasive evaluation of liver cirrhosis using ultrasound. Clin. Radiol., 2009, 64, 1056-1066.
104. Guha, I.N.; Myers, R.P.; Patel, K.; Talwalkar, J.A., Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology, 2011, 54, 1454-1462.
105. Reeder, S.B.; Cruite, I.; Hamilton, G.; Sirlin, C.B., Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J. Magn. Reson. Imaging, 2011, 34, 729-749.
106. Rogoveanu, I.; Gheonea, D.I.; Saftoiu, A.; Ciurea, T., The role of imaging methods in identifying the causes of extrahepatic cholestasis. J. Gastrointestin. Liver Dis., 2006, 15, 265-271.
107. Chen, C.P.; Haas-Kogan, D., Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Rev. Mol. Diagn., 2010, 10, 883-895.
108. Fartoux, L.; Decaens, T., Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol., 2011, 35, S21-S30.
109. Marrer, E.; Dieterle, F., Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol., 2010, 243, 167-179.
110. Ozer, J.; Ratner, M.; Shaw, M.; Bailey, W.; Schomaker, S., The current state of serum biomarkers of hepatotoxicity. Toxicology, 2008, 245, 194-205.
111. Williams, A.M.; Langley, P.G.; Osei-Hwediah, J.; Wendon, J.A.; Hughes, R.D., Hyaluronic acid and endothelial damage due to paracetamol-induced hepatotoxicity. Liver Int., 2003, 23, 110-115.
112. Yang, R.Z.; Blaileanu, G.; Hansen, B.C.; Shuldiner, A.R.; Gong, D.W., cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics, 2002, 79, 445-450.
113. Lindblom, P.; Rafter, I.; Copley, C.; Andersson, U.; Hedberg, J.J.; Berg, A.L.; Samuelsson, A.; Hellmold, H.; Cotgreave, I.; Glinghammar, B., Isoforms of alanine aminotransferases in human tissues and serum: differential tissue expression using novel antibodies. Arch. Biochem. Biophys., 2007, 466, 66-77.
114. Bataller-Sifre, R.; Guiral-Olivan, V.; Bataller-Alberola, L., New clinical and toxicological scenario of gammaglutamyltranspeptidase. Rev. Esp. Enferm. Dig., 2011, 103, 586-590.
115. Senior, J.R., Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin. Pharmacol. Ther., 2009, 85, 331-334.
116. Temple, R., Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf., 2006, 15, 241-243.
117. Kleiner, D.E., The pathology of drug-induced liver injury. Semin. Liv. Disease, 2009, 29, 364-372.
118. Bailey, W.J.; Ulrich, R., Molecular profiling approaches for identifying novel biomarkers. Expert Opin. Drug Saf., 2004, 3, 137-151.
119. Seggie, J.; Saunders, S.J.; Kirsch, R.E.; Campbell, J.A.; Gitlin, N.; Clain, D.; Terblanche, J., Patterns of hepatic injury induced by methyldopa. S. Afr. Med. J., 1979, 55, 75-83.
120. Moradpour, D.; Altorfer, J.; Flury, R.; Greminger, P.; Meyenberger, C.; Jost, R.; Schmid, M., Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology, 1994, 20, 1437-1441.
121. de Leval, L.; Lambermont, B.; D'Orio, V.; Boniver, J., Fatal massive liver steatosis: a clinicopathological case report. Acta Gastroenterol. Belg., 1997, 60, 180-183.
122. Larrey, D.; Freneaux, E.; Berson, A.; Babany, G.; Degott, C.; Valla, D.; Pessayre, D.; Benhamou, J.P., Peliosis hepatis induced by 6-thioguanine administration. Gut, 1988, 29, 1265-1269.
123. Buamah, P.K., An apparent danazol-induced primary hepatocellular carcinoma: case report. J. Surg. Oncol., 1985, 28, 114-116.
124. Fromenty, B.; Fisch, C.; Labbe, G.; Degott, C.; Deschamps, D.; Berson, A.; Letteron, P.; Pessayre, D., Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther., 1990, 255, 1371-1376.
125. Freneaux, E.; Labbe, G.; Letteron, P.; The Le, D.; Degott, C.; Geneve, J.; Larrey, D.; Pessayre, D., Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology, 1988, 8, 1056-1062.
126. Amacher, D.E., Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology, 2011, 279, 10-18.
127. Herishanu, Y.; Lishner, M.; Kitay-Cohen, Y., The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs, 2002, 13, 177-179.
128. Tsirigotis, P.; Sella, T.; Shapira, M.Y.; Bitan, M.; Bloom, A.; Kiselgoff, D.; Levin, M.; Libster, D.; Abdul Hai, A.; Gesundheit, B.; Or, R.; Slavin, S.; Resnick, I., Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes. Haematologica, 2007, 92, e106-e110.
129. Akbas, T.; Imeryuz, N.; Bayalan, F.; Baltacioglu, F.; Atagunduz, P.; Mulazimoglu, L.; Direskeneli, H., A case of Budd-Chiari syndrome with Behcet's disease and oral contraceptive usage. Rheumatol. Int., 2007, 28, 83-86.
130. Alonso-Marti, C.; Moreno, A.; Barat, A.; Solera, J.C.; Oliva, H., Co-existence of hepatocyte ground-glass inclusions from several causes. Histopathology, 1990, 16, 304-307.
131. Irie, H.; Mori, W., Long term effects of thorium dioxide (thorotrast) administration on human liver. Ultrastructural localization of thorium dioxide in human liver by analytical electron microscopy. Acta Pathol. Jpn., 1984, 34, 221-228.
132. Daly, A.K.; Day, C.P., Genetic association studies in drug-induced liver injury. Drug Metab. Rev., 2012, 44, 116-126.
133. Russmann, S.; Jetter, A.; Kullak-Ublick, G.A., Pharmacogenetics of drug-induced liver injury. Hepatology, 2010, 52, 748-761.
134. Hawkins, M.T.; Lewis, J.H., Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin. Drug Metab. Toxicol., 2012, 8, 1521-1530.
135. Vuilleumier, N.; Rossier, M.F.; Chiappe, A.; Degoumois, F.; Dayer, P.; Mermillod, B.; Nicod, L.; Desmeules, J.; Hochstrasser, D., CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol., 2006, 62, 423-429.
136. Huang, Y.S.; Su, W.J.; Huang, Y.H.; Chen, C.Y.; Chang, F.Y.; Lin, H.C.; Lee, S.D., Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione Stransferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol., 2007, 47, 128-134.
137. Andrade, R.J.; Lucena, M.I.; Alonso, A.; Garcia-Cortes, M.; Garcia-Ruiz, E.; Benitez, R.; Fernandez, M.C.; Pelaez, G.; Romero, M.; Corpas, R.; Duran, J.A.; Jimenez, M.; Rodrigo, L.; Nogueras, F.; Martin-Vivaldi, R.; Navarro, J.M.; Salmeron, J.; de la Cuesta, F.S.; Hidalgo, R., HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39, 1603-1612.
138. Hautekeete, M.L.; Horsmans, Y.; Van Waeyenberge, C.; Demanet, C.; Henrion, J.; Verbist, L.; Brenard, R.; Sempoux, C.; Michielsen, P.P.; Yap, P.S.; Rahier, J.; Geubel, A.P., HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology, 1999, 117, 1181-1186.
139. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe'er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; Graham, J.; Park, B.K.; Dillon, J.F.; Bernal, W.; Cordell, H.J.; Pirmohamed, M.; Aithal, G.P.; Day, C.P., HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 2009, 41, 816-819.
140. Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A.M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F.T., Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet, 2002, 359, 727-732.
141. Vinken, M.; De Rop, E.; Decrock, E.; De Vuyst, E.; Leybaert, L.; Vanhaecke, T.; Rogiers, V., Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet? Biochim. Biophys. Acta, 2009, 1795, 53-61.
142. Joanna, F.; van Grunsven, L.A.; Mathieu, V.; Sarah, S.; Sarah, D.; Karin, V.; Tamara, V.; Vera, R., Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J. Cell. Mol. Med., 2009, 13, 2990-3005.
143. Mandrekar, P., Epigenetic regulation in alcoholic liver disease. World J. Gastroenterol., 2011, 17, 2456-2464.
144. Kendrick, A.A.; Choudhury, M.; Rahman, S.M.; McCurdy, C.E.; Friederich, M.; Van Hove, J.L.; Watson, P.A.; Birdsey, N.; Bao, J.; Gius, D.; Sack, M.N.; Jing, E.; Kahn, C.R.; Friedman, J.E.; Jonscher, K.R., Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem. J., 2011, 433, 505-514.
145. Zhang, B.; Sun, S.; Shen, L.; Zu, X.; Chen, Y.; Hao, J.; Huang, X.; Feng, F., DNA methylation in the rat livers induced by low dosage isoniazid treatment. Environ. Toxicol. Pharmacol., 2011, 32, 486-490.
146. Kovalenko, V.M.; Bagnyukova, T.V.; Sergienko, O.V.; Bondarenko, L.B.; Shayakhmetova, G.M.; Matvienko, A.V.; Pogribny, I.P., Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol. Appl. Pharmacol., 2007, 225, 293-299.
147. Yokoi, T.; Nakajima, M., Toxicological implications of modulation of gene expression by microRNAs. Toxicol. Sci., 2011, 123, 1-14.
148. Jopling, C., Liver-specific microRNA-122: biogenesis and function. RNA Biol., 2012, 9, 137-142.
149. Wang, K.; Zhang, S.; Marzolf, B.; Troisch, P.; Brightman, A.; Hu, Z.; Hood, L.E.; Galas, D.J., Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA, 2009, 106, 4402-4407.
150. Starkey Lewis, P.J.; Dear, J.; Platt, V.; Simpson, K.J.; Craig, D.G.; Antoine, D.J.; French, N.S.; Dhaun, N.; Webb, D.J.; Costello, E.M.; Neoptolemos, J.P.; Moggs, J.; Goldring, C.E.; Park, B.K., Circulating microRNAs as potential markers of human druginduced liver injury. Hepatology, 2011, 54, 1767-1776.
151. Ruepp, S.; Boess, F.; Suter, L.; de Vera, M.C.; Steiner, G.; Steele, T.; Weiser, T.; Albertini, S., Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol., 2005, 207, 161-170.
152. Sawada, H.; Takami, K.; Asahi, S., A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci., 2005, 83, 282-292.
153. Huang, Q.; Jin, X.; Gaillard, E.T.; Knight, B.L.; Pack, F.D.; Stoltz, J.H.; Jayadev, S.; Blanchard, K.T., Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat. Res., 2004, 549, 147-167.
154. de Longueville, F.; Atienzar, F.A.; Marcq, L.; Dufrane, S.; Evrard, S.; Wouters, L.; Leroux, F.; Bertholet, V.; Gerin, B.; Whomsley, R.; Arnould, T.; Remacle, J.; Canning, M., Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci., 2003, 75, 378-392.
155. Bushel, P.R.; Heinloth, A.N.; Li, J.; Huang, L.; Chou, J.W.; Boorman, G.A.; Malarkey, D.E.; Houle, C.D.; Ward, S.M.; Wilson, R.E.; Fannin, R.D.; Russo, M.W.; Watkins, P.B.; Tennant, R.W.; Paules, R.S., Blood gene expression signatures predict exposure levels. Proc. Natl. Acad. Sci. USA, 2007, 104, 18211-18216.
156. Amacher, D.E., The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol., 2010, 245, 134-142.
157. van Summeren, A.; Renes, J.; van Delft, J.H.; Kleinjans, J.C.; Mariman, E.C., Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol. In Vitro, 2012, 26, 373-385.
158. Kikkawa, R.; Fujikawa, M.; Yamamoto, T.; Hamada, Y.; Yamada, H.; Horii, I., In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J. Toxicol. Sci., 2006, 31, 23-34.
159. Yamamoto, T.; Kikkawa, R.; Yamada, H.; Horii, I., Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J. Toxicol. Sci., 2005, 30, 213-227.
160. Kikkawa, R.; Yamamoto, T.; Fukushima, T.; Yamada, H.; Horii, I., Investigation of a hepatotoxicity screening system in primary cell cultures: "what biomarkers would need to be addressed to estimate toxicity in conventional and new approaches?". J. Toxicol. Sci., 2005, 30, 61-72.
161. Molleken, C.; Sitek, B.; Henkel, C.; Poschmann, G.; Sipos, B.; Wiese, S.; Warscheid, B.; Broelsch, C.; Reiser, M.; Friedman, S.L.; Tornoe, I.; Schlosser, A.; Kloppel, G.; Schmiegel, W.; Meyer, H.E.; Holmskov, U.; Stuhler, K., Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology, 2009, 49, 1257-1266.
162. Beger, R.D.; Sun, J.; Schnackenberg, L.K., Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol., 2010, 243, 154-166.
163. Fukuhara, K.; Ohno, A.; Ando, Y.; Yamoto, T.; Okuda, H., A 1H NMR-based metabolomics approach for mechanistic insight into acetaminophen-induced hepatotoxicity. Drug Metab. Pharmacokinet., 2011, 26, 399-406.
164. Kumar, B.S.; Chung, B.C.; Kwon, O.S.; Jung, B.H., Discovery of common urinary biomarkers for hepatotoxicity induced by carbon tetrachloride, acetaminophen and methotrexate by mass spectrometry-based metabolomics. J. Appl. Toxicol., 2012, 32, 505-520.
165. Sun, J.; Schnackenberg, L.K.; Beger, R.D., Studies of acetaminophen and metabolites in urine and their correlations with toxicity using metabolomics. Drug Metab. Lett., 2009, 3, 130-136.
166. Laverty, H.G.; Antoine, D.J.; Benson, C.; Chaponda, M.; Williams, D.; Kevin Park, B., The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur. J. Clin. Pharmacol., 2010, 66, 961-976.
167. Bell, L.N.; Chalasani, N., Epidemiology of idiosyncratic druginduced liver injury. Semin. Liv. Disease, 2009, 29, 337-347.
168. Nioi, P.; Perry, B.K.; Wang, E.J.; Gu, Y.Z.; Snyder, R.D., In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci., 2007, 99, 162-173.
169. Wang, K.; Lee, I.; Carlson, G.; Hood, L.; Galas, D., Systems biology and the discovery of diagnostic biomarkers. Dis. Markers, 2010, 28, 199-207.